{"id":235631,"date":"2026-09-08T17:04:48","date_gmt":"2026-09-08T11:34:48","guid":{"rendered":"https:\/\/univest.in\/blogs-2\/?p=235631"},"modified":"2026-09-08T17:04:48","modified_gmt":"2026-09-08T11:34:48","slug":"aarey-drugs-q2-results-fy27-preview-date-expectations","status":"publish","type":"post","link":"https:\/\/univest.in\/blogs-2\/aarey-drugs-q2-results-fy27-preview-date-expectations\/","title":{"rendered":"Aarey Drugs Q2 Results FY27 Preview: Results Date, Expectations and the Numbers That Will Decide the September 2026 Quarter"},"content":{"rendered":"<p style=\"border-left:4px solid #1F4E79;background:#EBF3FB;padding:10px 16px;font-style:italic;\"><em>Aarey Drugs share price Rs 98.03 on 8 September 2026, up 0.74%. Q2 FY27 results date not confirmed. Q1 FY27 net profit Rs 1.02 crore. Q2 FY26 base a profit of Rs 1.02 crore.<\/em><\/p>\n<div style=\"background:#F0F9FF;border-left:4px solid #2E7D32;border-radius:6px;padding:14px 18px;margin:18px 0;\">\n<p style=\"margin:0;color:#1F4E79;font-size:14px;\"><strong>Quick Answer<\/strong><\/p>\n<p style=\"margin:8px 0 0;\">The Aarey Drugs Q2 results date for FY27 is not confirmed, and Aarey Drugs &#038; Pharmaceuticals Ltd. had not filed a board meeting intimation with the NSE or BSE as of 8 September 2026. Indian listing rules require the September 2026 quarter results to be published within 45 days of the quarter end, an outer deadline of 14 November 2026. The quarter will be measured against a September 2025 base of Rs 84.16 crore in revenue and a profit of Rs 1.02 crore. This preview uses reported actuals only and carries no estimated revenue or profit figure for the coming quarter.<\/p>\n<\/p><\/div>\n<p>The Aarey Drugs Q2 results FY27 announcement is the next scheduled earnings event for <a href=\"https:\/\/univest.in\/stocks\/aareydrugs\/aarey-drugs-and-pharmaceuticals-ltd-share-price-today\">Aarey Drugs &#038; Pharmaceuticals Ltd.<\/a>, a manufacturer and trader of bulk drugs and pharmaceutical intermediates, with a large share of revenue coming from traded goods. The stock traded at Rs 98.03 on the NSE on 8 September 2026, up 0.74% from the previous close of Rs 97.31, about 2.0% below its 52-week high of Rs 100.00 and 94.9% above its 52-week low of Rs 50.31.<\/p>\n<p>What makes the Aarey Drugs Q2 results print worth watching is the base it faces. The September 2025 quarter delivered Rs 84.16 crore of revenue and a profit of Rs 1.02 crore, while the most recent quarter on record, Q1 FY27, produced Rs 44.63 crore and a profit of Rs 1.02 crore. Everything below is built from those reported figures rather than from any forecast.<\/p>\n<p style=\"margin-top:24px;\"><a href=\"https:\/\/univest.in\/user\/log-in?utm_source=blogs&#038;utm_medium=aareydrugs_q2_fy27\"><strong>Click Here &#8211; Get Free Investment Predictions<\/strong><\/a><\/p>\n<div id=\"ez-toc-container\" class=\"ez-toc-v2_0_65 counter-hierarchy ez-toc-counter ez-toc-grey ez-toc-container-direction\">\n<div class=\"ez-toc-title-container\">\n<p class=\"ez-toc-title \" >Table of Contents<\/p>\n<span class=\"ez-toc-title-toggle\"><a href=\"#\" class=\"ez-toc-pull-right ez-toc-btn ez-toc-btn-xs ez-toc-btn-default ez-toc-toggle\" aria-label=\"Toggle Table of Content\"><span class=\"ez-toc-js-icon-con\"><span class=\"\"><span class=\"eztoc-hide\" style=\"display:none;\">Toggle<\/span><span class=\"ez-toc-icon-toggle-span\"><svg style=\"fill: #999;color:#999\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\" class=\"list-377408\" width=\"20px\" height=\"20px\" viewBox=\"0 0 24 24\" fill=\"none\"><path d=\"M6 6H4v2h2V6zm14 0H8v2h12V6zM4 11h2v2H4v-2zm16 0H8v2h12v-2zM4 16h2v2H4v-2zm16 0H8v2h12v-2z\" fill=\"currentColor\"><\/path><\/svg><svg style=\"fill: #999;color:#999\" class=\"arrow-unsorted-368013\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\" width=\"10px\" height=\"10px\" viewBox=\"0 0 24 24\" version=\"1.2\" baseProfile=\"tiny\"><path d=\"M18.2 9.3l-6.2-6.3-6.2 6.3c-.2.2-.3.4-.3.7s.1.5.3.7c.2.2.4.3.7.3h11c.3 0 .5-.1.7-.3.2-.2.3-.5.3-.7s-.1-.5-.3-.7zM5.8 14.7l6.2 6.3 6.2-6.3c.2-.2.3-.5.3-.7s-.1-.5-.3-.7c-.2-.2-.4-.3-.7-.3h-11c-.3 0-.5.1-.7.3-.2.2-.3.5-.3.7s.1.5.3.7z\"\/><\/svg><\/span><\/span><\/span><\/a><\/span><\/div>\n<nav><ul class='ez-toc-list ez-toc-list-level-1 ' ><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-1\" href=\"https:\/\/univest.in\/blogs-2\/aarey-drugs-q2-results-fy27-preview-date-expectations\/#When_Is_the_Aarey_Drugs_Q2_Results_FY27_Date\" title=\"When Is the Aarey Drugs Q2 Results FY27 Date?\">When Is the Aarey Drugs Q2 Results FY27 Date?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-2\" href=\"https:\/\/univest.in\/blogs-2\/aarey-drugs-q2-results-fy27-preview-date-expectations\/#Aarey_Drugs_Q2_Results_Expectations_What_the_Market_Is_Actually_Tracking\" title=\"Aarey Drugs Q2 Results Expectations: What the Market Is Actually Tracking\">Aarey Drugs Q2 Results Expectations: What the Market Is Actually Tracking<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-3\" href=\"https:\/\/univest.in\/blogs-2\/aarey-drugs-q2-results-fy27-preview-date-expectations\/#Aarey_Drugs_Q2_Results_Preview_The_Q1_FY27_Actuals_It_Builds_On\" title=\"Aarey Drugs Q2 Results Preview: The Q1 FY27 Actuals It Builds On\">Aarey Drugs Q2 Results Preview: The Q1 FY27 Actuals It Builds On<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-4\" href=\"https:\/\/univest.in\/blogs-2\/aarey-drugs-q2-results-fy27-preview-date-expectations\/#Q2_FY26_Base_The_Comparison_Aarey_Drugs_Q2_Results_FY27_Must_Beat\" title=\"Q2 FY26 Base: The Comparison Aarey Drugs Q2 Results FY27 Must Beat\">Q2 FY26 Base: The Comparison Aarey Drugs Q2 Results FY27 Must Beat<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-5\" href=\"https:\/\/univest.in\/blogs-2\/aarey-drugs-q2-results-fy27-preview-date-expectations\/#Aarey_Drugs_Quarterly_Results_Trend_Over_the_Last_Four_Quarters\" title=\"Aarey Drugs Quarterly Results Trend Over the Last Four Quarters\">Aarey Drugs Quarterly Results Trend Over the Last Four Quarters<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-6\" href=\"https:\/\/univest.in\/blogs-2\/aarey-drugs-q2-results-fy27-preview-date-expectations\/#Key_Factors_That_Could_Shape_Aarey_Drugs_Q2_Results_FY27\" title=\"Key Factors That Could Shape Aarey Drugs Q2 Results FY27\">Key Factors That Could Shape Aarey Drugs Q2 Results FY27<\/a><ul class='ez-toc-list-level-3' ><li class='ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-7\" href=\"https:\/\/univest.in\/blogs-2\/aarey-drugs-q2-results-fy27-preview-date-expectations\/#Traded_Versus_Manufactured_Revenue\" title=\"Traded Versus Manufactured Revenue\">Traded Versus Manufactured Revenue<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-8\" href=\"https:\/\/univest.in\/blogs-2\/aarey-drugs-q2-results-fy27-preview-date-expectations\/#Valuation_Well_Above_the_Sector\" title=\"Valuation Well Above the Sector\">Valuation Well Above the Sector<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-9\" href=\"https:\/\/univest.in\/blogs-2\/aarey-drugs-q2-results-fy27-preview-date-expectations\/#Working_Capital_in_a_Trading-Led_Model\" title=\"Working Capital in a Trading-Led Model\">Working Capital in a Trading-Led Model<\/a><\/li><\/ul><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-10\" href=\"https:\/\/univest.in\/blogs-2\/aarey-drugs-q2-results-fy27-preview-date-expectations\/#Aarey_Drugs_Q2_Results_FY27_Share_Price_and_Valuation_Going_Into_the_Print\" title=\"Aarey Drugs Q2 Results FY27: Share Price and Valuation Going Into the Print\">Aarey Drugs Q2 Results FY27: Share Price and Valuation Going Into the Print<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-11\" href=\"https:\/\/univest.in\/blogs-2\/aarey-drugs-q2-results-fy27-preview-date-expectations\/#What_Investors_Should_Watch_When_Aarey_Drugs_Q2_Results_Are_Announced\" title=\"What Investors Should Watch When Aarey Drugs Q2 Results Are Announced\">What Investors Should Watch When Aarey Drugs Q2 Results Are Announced<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-12\" href=\"https:\/\/univest.in\/blogs-2\/aarey-drugs-q2-results-fy27-preview-date-expectations\/#Conclusion_on_Aarey_Drugs_Q2_Results_FY27\" title=\"Conclusion on Aarey Drugs Q2 Results FY27\">Conclusion on Aarey Drugs Q2 Results FY27<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-13\" href=\"https:\/\/univest.in\/blogs-2\/aarey-drugs-q2-results-fy27-preview-date-expectations\/#FAQs_on_Aarey_Drugs_Q2_Results_FY27\" title=\"FAQs on Aarey Drugs Q2 Results FY27\">FAQs on Aarey Drugs Q2 Results FY27<\/a><ul class='ez-toc-list-level-3' ><li class='ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-14\" href=\"https:\/\/univest.in\/blogs-2\/aarey-drugs-q2-results-fy27-preview-date-expectations\/#What_is_the_Aarey_Drugs_Q2_results_date_for_FY27\" title=\"What is the Aarey Drugs Q2 results date for FY27?\">What is the Aarey Drugs Q2 results date for FY27?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-15\" href=\"https:\/\/univest.in\/blogs-2\/aarey-drugs-q2-results-fy27-preview-date-expectations\/#What_quarter_do_the_Aarey_Drugs_Q2_results_2026_cover\" title=\"What quarter do the Aarey Drugs Q2 results 2026 cover?\">What quarter do the Aarey Drugs Q2 results 2026 cover?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-16\" href=\"https:\/\/univest.in\/blogs-2\/aarey-drugs-q2-results-fy27-preview-date-expectations\/#What_were_the_Aarey_Drugs_Q1_FY27_results\" title=\"What were the Aarey Drugs Q1 FY27 results?\">What were the Aarey Drugs Q1 FY27 results?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-17\" href=\"https:\/\/univest.in\/blogs-2\/aarey-drugs-q2-results-fy27-preview-date-expectations\/#What_were_Aarey_Drugs_Q2_FY26_results_in_the_September_2025_quarter\" title=\"What were Aarey Drugs Q2 FY26 results in the September 2025 quarter?\">What were Aarey Drugs Q2 FY26 results in the September 2025 quarter?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-18\" href=\"https:\/\/univest.in\/blogs-2\/aarey-drugs-q2-results-fy27-preview-date-expectations\/#What_are_the_main_Aarey_Drugs_Q2_results_expectations_this_quarter\" title=\"What are the main Aarey Drugs Q2 results expectations this quarter?\">What are the main Aarey Drugs Q2 results expectations this quarter?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-19\" href=\"https:\/\/univest.in\/blogs-2\/aarey-drugs-q2-results-fy27-preview-date-expectations\/#What_is_Aarey_Drugs_share_price_today_ahead_of_the_Q2_earnings\" title=\"What is Aarey Drugs share price today ahead of the Q2 earnings?\">What is Aarey Drugs share price today ahead of the Q2 earnings?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-20\" href=\"https:\/\/univest.in\/blogs-2\/aarey-drugs-q2-results-fy27-preview-date-expectations\/#Is_Aarey_Drugs_a_good_stock_to_buy_before_the_Q2_results\" title=\"Is Aarey Drugs a good stock to buy before the Q2 results?\">Is Aarey Drugs a good stock to buy before the Q2 results?<\/a><\/li><\/ul><\/li><\/ul><\/nav><\/div>\n<h2><span class=\"ez-toc-section\" id=\"When_Is_the_Aarey_Drugs_Q2_Results_FY27_Date\"><\/span><strong>When Is the Aarey Drugs Q2 Results FY27 Date?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p>The Aarey Drugs Q2 results date for FY27 is not confirmed. As of 8 September 2026, Aarey Drugs &#038; Pharmaceuticals Ltd. had not filed a board meeting intimation with the NSE or BSE for the September 2026 quarter, so any date circulating before that filing appears should be treated as unverified.<\/p>\n<p>What can be stated is the regulatory boundary. Listed companies in India must publish quarterly results within 45 days of the end of the quarter, which places the outer deadline for the September 2026 quarter at 14 November 2026. Companies also have to give the exchanges prior intimation of the board meeting that approves the results, so the Aarey Drugs Q2 results date becomes public through that filing rather than through any advance announcement.<\/p>\n<p>The Aarey Drugs Q2 results FY27 print covers 1 July 2026 to 30 September 2026. Small and mid-cap companies more often report in the second half of that window than in the first, so late October or early November is the range to watch for Aarey Drugs.<\/p>\n<h2><span class=\"ez-toc-section\" id=\"Aarey_Drugs_Q2_Results_Expectations_What_the_Market_Is_Actually_Tracking\"><\/span><strong>Aarey Drugs Q2 Results Expectations: What the Market Is Actually Tracking<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p>No verified analyst estimate for the Aarey Drugs Q2 results FY27 quarter is in the public domain, so no revenue or profit figure should be assumed for Aarey Drugs. The Aarey Drugs Q2 results watchlist below is built from what the company has actually reported and disclosed.<\/p>\n<p>The first is the revenue collapse in the June quarter. Aarey Drugs reported Rs 44.63 crore against Rs 189.47 crore in the March 2026 quarter, a fall of more than three quarters, and whether September returns to the earlier run rate is the single biggest question in this print.<\/p>\n<p>The second is what that swing says about the business mix. A large traded-goods component makes revenue lumpy because a single bulk transaction can dominate a quarter, so the composition disclosed in the filing matters more than the headline number.<\/p>\n<p>The third is that profit barely moved while revenue collapsed. Net profit was Rs 1.02 crore in June 2026 on revenue of Rs 44.63 crore, and Rs 1.56 crore in March on revenue of Rs 189.47 crore, which points to very different margins on different revenue streams.<\/p>\n<p style=\"margin-top:24px;\"><a href=\"https:\/\/univest.in\/screeners\"><strong>Check Aarey Drugs &#038; Pharmaceuticals Ltd. Live Fundamentals on the Univest Screener<\/strong><\/a><\/p>\n<h2><span class=\"ez-toc-section\" id=\"Aarey_Drugs_Q2_Results_Preview_The_Q1_FY27_Actuals_It_Builds_On\"><\/span><strong>Aarey Drugs Q2 Results Preview: The Q1 FY27 Actuals It Builds On<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p>Aarey Drugs &#038; Pharmaceuticals Ltd. reported revenue of Rs 44.63 crore in Q1 FY27, down 56.33% from Rs 102.21 crore in Q1 FY26, and a profit of Rs 1.02 crore at the net level, down 25.55% from Rs 1.37 crore in Q1 FY26. These are reported actuals, not estimates.<\/p>\n<p>Sequentially, revenue was down 76.44% over the March 2026 quarter figure of Rs 189.47 crore, and net profit was down 34.62% from Rs 1.56 crore in Q4 FY26. Operating margin stood at 3.6% in Q1 FY27 against 2.4% in the September 2025 quarter, which is the comparison the Aarey Drugs Q2 results print will be read against.<\/p>\n<h2><span class=\"ez-toc-section\" id=\"Q2_FY26_Base_The_Comparison_Aarey_Drugs_Q2_Results_FY27_Must_Beat\"><\/span><strong>Q2 FY26 Base: The Comparison Aarey Drugs Q2 Results FY27 Must Beat<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p>Aarey Drugs &#038; Pharmaceuticals Ltd. reported revenue of Rs 84.16 crore and a profit of Rs 1.02 crore in Q2 FY26, the September 2025 quarter. That is the year-ago base against which the September 2026 numbers will be judged, and it is the single most useful figure in this Aarey Drugs Q2 results preview.<\/p>\n<p>Net profit in that base quarter was below the Rs 1.02 crore just reported for Q1 FY27, so the year-on-year comparison starts from a manageable level. Revenue of Rs 84.16 crore sits above the Rs 44.63 crore of the June 2026 quarter, which frames how much sequential movement the Aarey Drugs Q2 results print needs to show growth.<\/p>\n<h2><span class=\"ez-toc-section\" id=\"Aarey_Drugs_Quarterly_Results_Trend_Over_the_Last_Four_Quarters\"><\/span><strong>Aarey Drugs Quarterly Results Trend Over the Last Four Quarters<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<table>\n<thead>\n<tr>\n<th>Quarter<\/th>\n<th>Revenue (Rs Cr)<\/th>\n<th>Net Profit (Rs Cr)<\/th>\n<\/tr>\n<\/thead>\n<tbody>\n<tr>\n<td>Q2 FY26 (Sep 2025)<\/td>\n<td>84.16<\/td>\n<td>1.02<\/td>\n<\/tr>\n<tr>\n<td>Q3 FY26 (Dec 2025)<\/td>\n<td>96.43<\/td>\n<td>0.57<\/td>\n<\/tr>\n<tr>\n<td>Q4 FY26 (Mar 2026)<\/td>\n<td>189.47<\/td>\n<td>1.56<\/td>\n<\/tr>\n<tr>\n<td>Q1 FY27 (Jun 2026)<\/td>\n<td>44.63<\/td>\n<td>1.02<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<p>Figures in brackets denote negative numbers. All four quarters above are reported actuals taken from the company&#8217;s exchange filings, and they are the only basis this Aarey Drugs Q2 results preview uses.<\/p>\n<p>Revenue across those four quarters ranged from Rs 44.63 crore to Rs 189.47 crore, and net profit from Rs 0.57 crore to Rs 1.56 crore. That spread is the honest context for the Aarey Drugs Q2 results FY27 print, and it is why a single quarter should not be read as a trend on its own.<\/p>\n<h2><span class=\"ez-toc-section\" id=\"Key_Factors_That_Could_Shape_Aarey_Drugs_Q2_Results_FY27\"><\/span><strong>Key Factors That Could Shape Aarey Drugs Q2 Results FY27<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p>The Aarey Drugs Q2 results outcome will turn on a small number of company-specific variables rather than on broad market conditions. The three below are the ones visible in what Aarey Drugs has already reported.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"Traded_Versus_Manufactured_Revenue\"><\/span><strong>Traded Versus Manufactured Revenue<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p>Revenue has ranged from Rs 44.63 crore to Rs 189.47 crore in five quarters while profit stayed between Rs 0.57 crore and Rs 1.56 crore. That pattern is typical of a business where low-margin trading inflates the top line without adding much to the bottom line.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"Valuation_Well_Above_the_Sector\"><\/span><strong>Valuation Well Above the Sector<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p>Aarey Drugs trades at a price-to-earnings ratio of 72.34 against a sector average of 37.70, on a return on equity of 2.75%. The stock has also run to a 14-day RSI of 75.53 and sits close to its 52-week high of Rs 100.00, so expectations going into the print are elevated.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"Working_Capital_in_a_Trading-Led_Model\"><\/span><strong>Working Capital in a Trading-Led Model<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p>Bulk drug trading absorbs working capital, and receivables and inventory disclosed with the results tell more about cash generation than the profit line does. A debt-to-equity ratio of 0.31 leaves some headroom but not unlimited room.<\/p>\n<h2><span class=\"ez-toc-section\" id=\"Aarey_Drugs_Q2_Results_FY27_Share_Price_and_Valuation_Going_Into_the_Print\"><\/span><strong>Aarey Drugs Q2 Results FY27: Share Price and Valuation Going Into the Print<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p>Aarey Drugs share price today is Rs 98.03 on the NSE, up Rs 0.72 or 0.74% from the previous close of Rs 97.31 on 8 September 2026, ahead of the Aarey Drugs Q2 results announcement.<\/p>\n<table>\n<thead>\n<tr>\n<th>Metric<\/th>\n<th>Value (8 September 2026)<\/th>\n<\/tr>\n<\/thead>\n<tbody>\n<tr>\n<td>NSE Symbol<\/td>\n<td>AAREYDRUGS<\/td>\n<\/tr>\n<tr>\n<td>Current Market Price<\/td>\n<td>Rs 98.03<\/td>\n<\/tr>\n<tr>\n<td>52-Week High<\/td>\n<td>Rs 100.00<\/td>\n<\/tr>\n<tr>\n<td>52-Week Low<\/td>\n<td>Rs 50.31<\/td>\n<\/tr>\n<tr>\n<td>Market Capitalisation<\/td>\n<td>Rs 302 crore<\/td>\n<\/tr>\n<tr>\n<td>PE Ratio<\/td>\n<td>72.34<\/td>\n<\/tr>\n<tr>\n<td>Sector PE<\/td>\n<td>37.70<\/td>\n<\/tr>\n<tr>\n<td>PB Ratio<\/td>\n<td>1.85<\/td>\n<\/tr>\n<tr>\n<td>EPS (TTM)<\/td>\n<td>Rs 1.35<\/td>\n<\/tr>\n<tr>\n<td>Book Value per Share<\/td>\n<td>Rs 53.00<\/td>\n<\/tr>\n<tr>\n<td>Debt to Equity<\/td>\n<td>0.31<\/td>\n<\/tr>\n<tr>\n<td>Return on Equity<\/td>\n<td>2.75%<\/td>\n<\/tr>\n<tr>\n<td>50-Day Moving Average<\/td>\n<td>Rs 83.21<\/td>\n<\/tr>\n<tr>\n<td>200-Day Moving Average<\/td>\n<td>Rs 77.07<\/td>\n<\/tr>\n<tr>\n<td>RSI (14)<\/td>\n<td>75.53<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<p>The stock trades above both its 50-day average of Rs 83.21 and its 200-day average of Rs 77.07, with a 14-day RSI of 75.53. None of this is a view on where the shares go once the Aarey Drugs Q2 results are announced, and no price target is offered here.<\/p>\n<p style=\"margin-top:24px;\"><em>Download the <a href=\"http:\/\/apps.apple.com\/in\/app\/univest-stocks-investment\/id6443753518\" rel=\"nofollow noopener\" target=\"_blank\">Univest iOS App<\/a> or <a href=\"http:\/\/play.google.com\/store\/apps\/details?id=com.univest.capp&#038;hl=en_IN\" rel=\"nofollow noopener\" target=\"_blank\">Univest Android App<\/a> to track Aarey Drugs &#038; Pharmaceuticals Ltd. live price and quarterly earnings updates.<\/em><\/p>\n<h2><span class=\"ez-toc-section\" id=\"What_Investors_Should_Watch_When_Aarey_Drugs_Q2_Results_Are_Announced\"><\/span><strong>What Investors Should Watch When Aarey Drugs Q2 Results Are Announced<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p>Four lines carry most of the information in a company of this size, and reading them in order keeps the Aarey Drugs Q2 results print in proportion.<\/p>\n<ol>\n<li>Revenue against the Rs 84.16 crore reported in the September 2025 base quarter<\/li>\n<li>Net profit against a profit of Rs 1.02 crore in that same quarter<\/li>\n<li>Operating margin against 3.6% in Q1 FY27<\/li>\n<li>Any exceptional item, provision or one-off gain disclosed alongside the numbers<\/li>\n<\/ol>\n<p>A one-off gain or provision can move the reported profit far more than operations do in a company this size, which is why the Aarey Drugs Q2 results announcement should be read together with the notes to the results rather than the headline alone.<\/p>\n<h2><span class=\"ez-toc-section\" id=\"Conclusion_on_Aarey_Drugs_Q2_Results_FY27\"><\/span><strong>Conclusion on Aarey Drugs Q2 Results FY27<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p>The Aarey Drugs Q2 results date is not confirmed, and 14 November 2026 is the statutory outer limit rather than an expected date. Aarey Drugs &#038; Pharmaceuticals Ltd. will make the schedule public through a board meeting intimation to the exchanges, and until then the September 2026 quarter can only be framed by what has already been reported.<\/p>\n<p>On that basis the Aarey Drugs Q2 results FY27 print faces a base of Rs 84.16 crore in revenue and a profit of Rs 1.02 crore, with the most recent quarter having delivered Rs 44.63 crore and a profit of Rs 1.02 crore. No numerical estimate appears in this preview because no verified consensus figure exists for Aarey Drugs, and readers should treat any preview that supplies one with caution. Verify every figure against the company filing on release and consult a SEBI-registered advisor before acting on quarterly earnings.<\/p>\n<div style=\"background:#CC0000;border-radius:8px;padding:16px 20px;margin:24px 0;\">\n<p style=\"color:#FFFFFF;font-size:13px;line-height:1.7;margin:0;\"><strong style=\"color:#FFFFFF;\">Disclaimer:<\/strong> Data and figures in this article are sourced from publicly available information. These may or may not be accurate. Please verify all data with the official NSE (nseindia.com) and BSE (bseindia.com) websites before making any investment decision. Investments in securities are subject to market risk. This content is for educational purposes only and is not investment advice by Univest (SEBI RA INH000013776).<\/p>\n<\/p><\/div>\n<h2><span class=\"ez-toc-section\" id=\"FAQs_on_Aarey_Drugs_Q2_Results_FY27\"><\/span><strong>FAQs on Aarey Drugs Q2 Results FY27<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<h3><span class=\"ez-toc-section\" id=\"What_is_the_Aarey_Drugs_Q2_results_date_for_FY27\"><\/span><strong>What is the Aarey Drugs Q2 results date for FY27?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p><strong>Ans.<\/strong> The Aarey Drugs Q2 results date for FY27 is not confirmed. Aarey Drugs &#038; Pharmaceuticals Ltd. had not filed a board meeting intimation with the NSE or BSE as of 8 September 2026. Indian listing rules require the September 2026 quarter results to be published by 14 November 2026 at the latest.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"What_quarter_do_the_Aarey_Drugs_Q2_results_2026_cover\"><\/span><strong>What quarter do the Aarey Drugs Q2 results 2026 cover?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p><strong>Ans.<\/strong> The Aarey Drugs Q2 results FY27 cover 1 July 2026 to 30 September 2026, known as the September 2026 quarter. Aarey Drugs &#038; Pharmaceuticals Ltd. reports revenue, operating profit and net profit for that period, and the Aarey Drugs Q2 results filing also carries the notes to the accounts.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"What_were_the_Aarey_Drugs_Q1_FY27_results\"><\/span><strong>What were the Aarey Drugs Q1 FY27 results?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p><strong>Ans.<\/strong> Aarey Drugs &#038; Pharmaceuticals Ltd. reported revenue of Rs 44.63 crore in Q1 FY27 and a profit of Rs 1.02 crore at the net level. Revenue was down 56.33% versus Q1 FY26 and net profit was down 25.55% from Rs 1.37 crore in Q1 FY26.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"What_were_Aarey_Drugs_Q2_FY26_results_in_the_September_2025_quarter\"><\/span><strong>What were Aarey Drugs Q2 FY26 results in the September 2025 quarter?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p><strong>Ans.<\/strong> Aarey Drugs &#038; Pharmaceuticals Ltd. reported revenue of Rs 84.16 crore and a profit of Rs 1.02 crore in Q2 FY26. Operating margin was 2.4%. Those figures form the base for the Aarey Drugs Q2 results FY27 comparison.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"What_are_the_main_Aarey_Drugs_Q2_results_expectations_this_quarter\"><\/span><strong>What are the main Aarey Drugs Q2 results expectations this quarter?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p><strong>Ans.<\/strong> No verified analyst estimate is publicly available. The Aarey Drugs Q2 results expectations centre on revenue against the Rs 84.16 crore base, net profit against a profit of Rs 1.02 crore, operating margin against 3.6% in Q1 FY27, and any exceptional item disclosed with the numbers.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"What_is_Aarey_Drugs_share_price_today_ahead_of_the_Q2_earnings\"><\/span><strong>What is Aarey Drugs share price today ahead of the Q2 earnings?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p><strong>Ans.<\/strong> Aarey Drugs share price is Rs 98.03 on the NSE as of 8 September 2026, up 0.74% from Rs 97.31. The stock is about 2.0% below its 52-week high of Rs 100.00 and 94.9% above its 52-week low of Rs 50.31, at a market capitalisation of Rs 302 crore.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"Is_Aarey_Drugs_a_good_stock_to_buy_before_the_Q2_results\"><\/span><strong>Is Aarey Drugs a good stock to buy before the Q2 results?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p><strong>Ans.<\/strong> This article does not offer a buy, sell or hold recommendation on Aarey Drugs &#038; Pharmaceuticals Ltd.. The stock trades at a price-to-book ratio of 1.85 with a return on equity of 2.75%. Assess the reported numbers when they are released and consult a SEBI-registered financial advisor before making any decision.<\/p>\n<div class=\"faq-schema\"><script type=\"application\/ld+json\">{\"@context\":\"https:\/\/schema.org\",\"@type\":\"FAQPage\",\"mainEntity\":[{\"@type\":\"Question\",\"name\":\"What is the Aarey Drugs Q2 results date for FY27?\",\"acceptedAnswer\":{\"@type\":\"Answer\",\"text\":\"The Aarey Drugs Q2 results date for FY27 is not confirmed. Aarey Drugs & Pharmaceuticals Ltd. had not filed a board meeting intimation with the NSE or BSE as of 8 September 2026. Indian listing rules require the September 2026 quarter results to be published by 14 November 2026 at the latest.\"}},{\"@type\":\"Question\",\"name\":\"What quarter do the Aarey Drugs Q2 results 2026 cover?\",\"acceptedAnswer\":{\"@type\":\"Answer\",\"text\":\"The Aarey Drugs Q2 results FY27 cover 1 July 2026 to 30 September 2026, known as the September 2026 quarter. Aarey Drugs & Pharmaceuticals Ltd. reports revenue, operating profit and net profit for that period, and the Aarey Drugs Q2 results filing also carries the notes to the accounts.\"}},{\"@type\":\"Question\",\"name\":\"What were the Aarey Drugs Q1 FY27 results?\",\"acceptedAnswer\":{\"@type\":\"Answer\",\"text\":\"Aarey Drugs & Pharmaceuticals Ltd. reported revenue of Rs 44.63 crore in Q1 FY27 and a profit of Rs 1.02 crore at the net level. Revenue was down 56.33% versus Q1 FY26 and net profit was down 25.55% from Rs 1.37 crore in Q1 FY26.\"}},{\"@type\":\"Question\",\"name\":\"What were Aarey Drugs Q2 FY26 results in the September 2025 quarter?\",\"acceptedAnswer\":{\"@type\":\"Answer\",\"text\":\"Aarey Drugs & Pharmaceuticals Ltd. reported revenue of Rs 84.16 crore and a profit of Rs 1.02 crore in Q2 FY26. Operating margin was 2.4%. Those figures form the base for the Aarey Drugs Q2 results FY27 comparison.\"}},{\"@type\":\"Question\",\"name\":\"What are the main Aarey Drugs Q2 results expectations this quarter?\",\"acceptedAnswer\":{\"@type\":\"Answer\",\"text\":\"No verified analyst estimate is publicly available. The Aarey Drugs Q2 results expectations centre on revenue against the Rs 84.16 crore base, net profit against a profit of Rs 1.02 crore, operating margin against 3.6% in Q1 FY27, and any exceptional item disclosed with the numbers.\"}},{\"@type\":\"Question\",\"name\":\"What is Aarey Drugs share price today ahead of the Q2 earnings?\",\"acceptedAnswer\":{\"@type\":\"Answer\",\"text\":\"Aarey Drugs share price is Rs 98.03 on the NSE as of 8 September 2026, up 0.74% from Rs 97.31. The stock is about 2.0% below its 52-week high of Rs 100.00 and 94.9% above its 52-week low of Rs 50.31, at a market capitalisation of Rs 302 crore.\"}},{\"@type\":\"Question\",\"name\":\"Is Aarey Drugs a good stock to buy before the Q2 results?\",\"acceptedAnswer\":{\"@type\":\"Answer\",\"text\":\"This article does not offer a buy, sell or hold recommendation on Aarey Drugs & Pharmaceuticals Ltd.. The stock trades at a price-to-book ratio of 1.85 with a return on equity of 2.75%. Assess the reported numbers when they are released and consult a SEBI-registered financial advisor before making any decision.\"}}]}<\/script><\/div>\n","protected":false},"excerpt":{"rendered":"<p>Aarey Drugs Q2 results FY27 date is not yet confirmed by the exchanges. Here is the September 2026 quarter watchlist for Aarey Drugs &#038; Pharmaceuticals Ltd., built on actual Q1 FY27 and Q2 FY26 numbers with no invented estimates.<\/p>\n","protected":false},"author":29,"featured_media":235630,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[5331],"tags":[],"class_list":["post-235631","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-https-univest-in-blogs-category-results"],"metadata":{"rank_math_internal_links_processed":["1"],"_thumbnail_id":["235630"],"rank_math_title":["Aarey Drugs Q2 Results FY27: Date and Expectations"],"rank_math_description":["Aarey Drugs Q2 results FY27 preview: results date status, key expectations, Q1 FY27 and Q2 FY26 actuals, factors to watch and valuation ahead of the September 2026 print."],"rank_math_focus_keyword":["Aarey Drugs Q2 results"],"rank_math_robots":["a:2:{i:0;s:7:\"noindex\";i:1;s:8:\"nofollow\";}"]},"jetpack_sharing_enabled":true,"jetpack_featured_media_url":"https:\/\/univest.in\/blogs-2\/wp-content\/uploads\/2026\/09\/aarey-drugs-q2-results-fy27-preview-date-expectations.png","_links":{"self":[{"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/posts\/235631","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/users\/29"}],"replies":[{"embeddable":true,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/comments?post=235631"}],"version-history":[{"count":1,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/posts\/235631\/revisions"}],"predecessor-version":[{"id":235632,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/posts\/235631\/revisions\/235632"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/media\/235630"}],"wp:attachment":[{"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/media?parent=235631"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/categories?post=235631"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/tags?post=235631"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}